-transparent.png){kind=logo}
OBJECTIVE To study the antitumor activity of sobuzoxane (Sob) in combination with doxorubicin (Dox) and the effect of Sob on Dox-induced cardiotoxicity. METHODS DBA/2 mice bearing transplanted leukemia P388 were given i.v. Dox 2 mg.kg-1.d-1 for 3 d, 4 mg.kg-1.d-1 for 1 d combined with ig Sob 20, 40 mg.kg-1.d-1 for 7 d. The increase in life span (ILS) of each group was recorded in 30 d. The myocardium of moribund mice was examined by transmission electron microscopy. RESULTS The ILS of combination therapeutic groups of Sob with Dox was 48.7%, 57.3%, 59.0%, and 62.4% respectively, which were 30%-90% higher than the sum of ILS of two groups treated with Dox and Sob separately (P < 0.01). The ultrastructural injury of cardiomyocytes of P388-bearing mice caused by combination chemotherapy with Dox plus Sob was markedly attenuated compared with Dox alone. CONCLUSIONS Sob with Dox exhibited an antitumor synergistic effect on leukemia P388, and the cardiotoxicity of Dox was reduced by Sob.
Z Q Dai, and
J Y Xu, and
X J Yuan, and
J C Cai
July 1986,
Cancer research,
Z Q Dai, and
J Y Xu, and
X J Yuan, and
J C Cai
September 1994,
Cancer biochemistry biophysics,
Z Q Dai, and
J Y Xu, and
X J Yuan, and
J C Cai
October 1993,
Anti-cancer drugs,
Z Q Dai, and
J Y Xu, and
X J Yuan, and
J C Cai
March 1981,
Journal of medicinal chemistry,
Z Q Dai, and
J Y Xu, and
X J Yuan, and
J C Cai
January 1987,
NCI monographs : a publication of the National Cancer Institute,
Z Q Dai, and
J Y Xu, and
X J Yuan, and
J C Cai
January 1982,
Journal of interferon research,
Z Q Dai, and
J Y Xu, and
X J Yuan, and
J C Cai
December 1990,
Research communications in chemical pathology and pharmacology,
Z Q Dai, and
J Y Xu, and
X J Yuan, and
J C Cai
May 1985,
Cancer treatment reports,
Z Q Dai, and
J Y Xu, and
X J Yuan, and
J C Cai
December 1990,
Japanese journal of pharmacology,
Z Q Dai, and
J Y Xu, and
X J Yuan, and
J C Cai
January 1990,
Oncology,
